Research-use versus therapeutic-use distinctions The regulatory distinction between research use and therapeutic use of peptides is significant in Australian law
However, when IGFBP-1 levels are chronically lowered during prolonged intra-portal hyperinsulinemia (e.g., obesity, Cushings syndrome and glucocorticoid therapy), the accelerator effect of IGFBP-1 is at play to increase serum free IGF-I (35, 40)
A 2020 meta-analysis of 37 randomized trials found an average body-weight reduction of 1.21 kg, with the clearest dose-response signal around 2,000 mg per day
Some patients benefit most from a single targeted peptide, while others respond well to a combination approach
First, it included treatment groups that were well-balanced on the most relevant prognostic factors